Form 4: AbbVie Director Edward J. Rapp Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Edward J. Rapp reports acquisition of stock equivalent units and adjustments to holdings in AbbVie Inc.
Summary
- On September 30, 2024, Edward J. Rapp, a director of AbbVie Inc., acquired 164 stock equivalent units at a price of $197.48.
- These units were obtained as director fees credited to a stock equivalent unit account under a grantor trust.
- The units earn the same return as if the fees were invested in AbbVie stock and are generally paid in cash at age 65 or upon retirement from the board.
- Following the transaction, Rapp's direct ownership includes 26,544 stock equivalent units, which includes units acquired through dividend reinvestment.
- The reporting was filed on October 2, 2024.
Sentiment
Score: 5
Explanation: This is a neutral report on stock ownership changes, with no inherent positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure related to director compensation and holdings, typical for publicly traded companies like AbbVie. It provides transparency into the equity ownership of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director compensation and alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of transaction: Acquisition of stock equivalent units. |
| 10/02/2024 | Date of filing: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.